Physician profile
Ronald D Liskanich
NPI 1245391820
$23,777.37
in general payments reported to CMS, 2019-2025
44 companies · $3,370 in 2025
The $3,370 reported for 2025 was more than what 85% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,922 · 2020: $1,180 · 2021: $2,148 · 2022: $3,563 · 2023: $4,426 · 2024: $4,168 · 2025: $3,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,574.43 |
| Education | $389.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,865.35 | 2019-2025 | |
| Pfizer INC. | $1,610.74 | 2019-2025 | |
| Leo Pharma INC. | $1,606.83 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $1,592.37 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $1,401.53 | 2019-2025 | |
| Amgen INC. | $1,274.96 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $933.36 | 2020-2025 | Olumiant, Ebglyss, Taltz |
| Dermavant Sciences, INC. | $906.02 | 2022-2024 | Vtama |
| Incyte Corporation | $820.60 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $772.51 | 2019-2025 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $727.15 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $698.73 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $692.26 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Epi Health, LLC | $688.90 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $682.08 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Liskanich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.